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ABSTRACT

The use of camptothecin (CPT), hyperoside and/ or trifolin in

preventing or inhibiting the growth of fungal pathogens,
including molds.
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METHODS FOR INHIBITING FUNGAL
PATHOGEN INFESTATION AND PROPOGATION

in their susceptibility to leaf spot, but the primary symptom
of a leaf spot disease typically comes as broWn spots on

foliage.
BACKGROUND OF THE INVENTION

[0001]

1. Field of The Invention

[0002] Applicant’s invention generally relates to the ?eld

[0012]

Leaf spot diseases are caused by a variety of fungal

pathogens Which can survive from year to year as spores or

mycelium (fungal threads) in dead plant debris, in the thatch

of plant pathology. Speci?cally, the proposed invention

layer, and in infected plant parts. Once into the leaf, the
fungi continue to groW and leaf tissue is destroyed. Spots

includes compositions, processes for their production, and
methods for their use in controlling certain plant fungal

tend to groW and multiply to the point that they merge to

pathogens, including molds.
[0003] 2. Background Information
[0004]

a. Fungal Infestation

[0005] Fungal infestations (largely of the subset of
“molds”) in the plant realm come in a Wide variety of forms
and they, as Well as, in some cases, the conventional
measures to combat them, extract an enormous toll, eco

nomically, aesthetically and environmentally.
[0006] The mold subset of fungus share the characteristics
of forming a mycelium, but lacking a sporocarp. Mold
spores are ubiquitious, germinate quickly and often quickly

substrates rapidly.

become a “blight” or a “blotch.” Partial to complete defo
liation of the plant may occur under conditions Which are

favorable for the causal fungus.

[0013]

If to be even partly e?fective, presently available

fungicides must be applied as a protectant before the fungus
spore is disseminated to the leaf. Optimal, though incom
plete control of fungal infestations through use of conven

tional fungicides usually requires tWo to three spray appli

cations, With additional applications typically shoWing
nominal, if any greater e?icacy, and/or e?fecting one or more
undesirable side e?fects in the plants or surrounding envi
ronment Which outWeigh any advantages of further use.

[0014] Root rot is another product of fungal infestation
and, like leaf spot, arises from several different species of
fungus that are common to ?eld soil, sand, pond and stream

[0007] In the food realm, (e.g., bread, cheese, peaches) or
manufactured goods of organic origin, molds represent an
often serious health haZard. By Way of example, Allernaria,
Epicoccum, Drechslera, and Fusarium are all objects of

Water and their sediments, as Well as in dead roots of

allergies (sometimes life-threatening allergies) in many
humans.

roots and occasionally the larger roots. Root rot is di?icult
to control once it has begun.

[0008] Agricultural, horticultural and forest plants are also
threatened by fungal pathogens native to the United States as
Well as invasive fungi from other countries. Thus, the export

[0015] Of particular note in the root rot context is
Fusarium, Which is a genus of fungi and a Well-knoWn plant
pathogen. Fusarium Wilt a?fects many di?ferent horticultural

previous crops. Root rot is typically fatal for the infected

plants, With earlier symptoms including Wilting, yelloWing
and retention of dried foliage and darkening of young feeder

of agricultural crops from the United States to other coun

plants and is the most important pathological problem of

tries is sometimes in?uenced by the presence/absence of

plants groWn in arti?cial groWing media. Fusarium is a
?lamentous fungus that is Widely distributed on plants and
in the soil. Several different species of Fusarium (including

fungi of importance in relation to plant quarantine regula
tions.

F oxysporum, F solani, and F avenaceum) can cause root

[0009] According to the 2003 report of the Agricultural
Research Service of the US. Department of Agriculture,
economic loss to agricultural and horticultural crops from
disease-causing fungi is estimated at $20 billion per year in

the United States. In addition, fungi often limit U.S. agri
cultural exports, a signi?cant negative factor for the US. in
the over-all balance of trade.

rot of, among other things, container tree seedlings.
[0016]

Fusarium root rot is one of the most common

diseases of seedlings in the World and is Widespread in North
American nurseries. Most conifer seedlings, including
spruces, true ?rs, pines and larch are susceptible to
Fusarium root rot. Fungicidal drenches are commonly used
in attempts to control Fusarium root rot, but these treatments

[0010] Currently available, broad-spectrum fungicides are

function primarily to impede the spread of the infestation,

mostly synthetic, and are of limited e?icacy and/or are

and rarely are there any indications of an actual reversal of
an existing infestation.

environmentally pernicious, e.g., chlorothalonil (Daconil
Ultrex, Daconil Zn, Daconil Weather Stikiuse of these

0017

b. CamP lolheca acuminala and camP tothecin

products on home laWns is prohibited), iprodione (Chipco
260l9iprohibited at residential sites), mancoZeb (Fore),

(CPT).

maneb, ?xed coppers and Zineb. The most e?‘ective fungi
cide applications may provide only a 50-60% reduction in
the above-described diseases. Ironically, application of some

Nyssaceae (tupelo family). This fast-groWing, deciduous
tree is native only to China and Tibet. This tree (along With

major herbicides even increased the presence of Fusarium in
crops.

for a potent anti-leukemia and anti-tumor ingredientia

[0011] Among the fungal disease categories of paramount

modi?ed to create many other anti-cancer drugs, including

concern to society is that knoWn as “leaf spot.” Leaf spot is
a common descriptive term applied to a number of Wide

[0018]

Camplolheca acuminala is a member of the family

some alternative sources to be discussed beloW) is a source

quinoline alkaloid called camptothecin (CPT). CPT has been

irinotecan, topotecan, 9-aminocamptothecin, and CPT-ll.

spread and destructive fungal diseases Which a?cect virtually

[0019] CPT and these analogs are being investigated to

all commonly groWn trees and shrubs. Plant varieties dilfer

treat a Wide variety of cancers, but the compounds are quite
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toxic. Only topotecan (Hycamtin®) and irinotecan HCl
(Camptosar®) have met With FDA approval; Hycamtine®
has been approved for ovarian cancer therapy, and Camp

degree possible, environmentally benign. Also needed are
method(s) to economically produce such agents or compo
sitions.

tosar® is approved for metastatic colorectal cancers.
SUMMARY OF THE INVENTION

[0020] Leaf spots caused by Allernaria, Epicoccum, and
Peslalolia, as Well as root rots caused by Fusarium, are

[0028]

major fungal diseases affecting biomass and CPT production
in Camplolheca cultivation.

compositions for controlling plant fungal pathogens.
[0029]

It is an object of the present invention to provide
It is an object of the present invention to provide

Leaf spots often increase in severity as the growing

compositions for more effectively controlling plant fungal

season progresses and leaves become mature. Leaves die

pathogens than is possible through use of presently available

and drop off prematurely, and the all-important CPT yields

compositions or methods.

[0021]

are decreased as a result of the diseased plant’s decreased

[0030]

It is another object of the present invention to

ability to carry out photosynthesis.

provide compositions for controlling plant fungal pathogens,

[0022] Contributing fungal factors in leaf spot in Camp

Which compositions are more environmentally benign than
presently-available compositions of similar intended use.

Zolheca include E. nigrum. E. nigrum is a cosmopolitan

saprophyte found on many plants, textiles, paper products,
and foodstuff, in soils and air samples. R guepinii is prima
rily a secondary pathogen. It is saprophytic on dead and

dying tissues and is Weakly parasitic, infecting through
Wounds under moist conditions. Drechslera spp. are either

plant pathogens or saprobes. Fusarium, as previously men
tioned, is a soil borne fungus With WorldWide distribution,

particularly throughout tropical and subtropical areas.
[0023]

c. Present Anti-fungal Research and Conventional

Anti-fungal Measures.
[0024] Dithiocarbamates are organic fungicides com
monly used for the treatment of soil, seeds, and foliar and
postharvest diseases of some crops. Dithiocarbamates,

including Maneb, N,N-diethyldithiocarbamic acid sodium
salt, and some neWly synthetic compounds, are shoWn to
inhibit groWth of F oxysporum f. sp. lini, but only by 7-30%
at the concentration of 100 ppm (100 ug/mL).

[0031] It is another object of the present invention to
provide a method for producing compositions for controlling

plant fungal pathogens.
[0032] It is another object of the present invention to
provide a method for producing compositions for more

effectively controlling plant fungal pathogens than is pos
sible through use of presently available compositions or
methods.

[0033] It is another object of the present invention to
provide a method for producing compositions for controlling
plant fungal pathogens, Which compositions are more envi

ronmentally benign than presently-available compositions
of similar intended use.

[0034]

It is another object of the present invention to

provide a method for controlling plant fungal pathogens
more effective than is possible through use of presently
available compositions or methods.

[0025] As the most potent antifungal compound of the

[0035]

essential oils of 13 herbs selected by Sridhar et al. (2003),

provide a method for controlling plant fungal pathogens,

geraniol isolated from cymbopogan (Cymbopogan martini)

Which compositions are more environmentally benign than
are presently-available compositions of similar intended use.

inhibited groWth of Bolrylis cinerea in both in vitro tests and
TLC bioautography With a minimum concentration of 160

ug/mL (MIC). Essential oils of Salvia sclarea L. (Lami
aceae) inhibited groWth of F oxysporum f. sp. dianthi by
72% at concentrations of 2,000 uL/L. [3-Asarone from
rhiZomes of Acorus gramineus Solander (Araceae) Was

[0036]

It is another object of the present invention to

It is another object of the present invention to

provide a method for controlling plant fungal pathogens
more cost-effective than is possible through use of presently
available compositions or methods.

effective against mycelial groWth of Allernaria mali (With
MIC>l00 ug/mL) and F oxysporum f.sp. lycopersici (With
MIC>l00 ug/mL). Vanillin, 4-hydroxy-3-methoxycinnama
ldehyde, and (1) pinoresinol isolated from Melia aZedarach

Applicant’s present invention provides compositions, meth

L. (Meliaceae) controlledF verlicillioides at higher concen

objects, and individually meet at least a subset of such

trations (With MICs of 600, 400, and 1,000 ug/mL, respec

objects.

tively).
[0026] Despite the limited ef?cacy of the above-described
anti-fungal agents, and in particular vieW of the dramatic

[0037]

In satisfaction of these and related objectives,

ods for producing compositions, and method of use of such

compositions Which collectively satisfy all of the above

[0038] The present invention relates to camptothecin
(CPT) and the ?avonoids trifolin and hyperoside, all isolated
from plants knoWn to contain same. All experimental data

fungicide is particularly effective against leaf spots and root

to-data arises extraction from Camplolheca., hoWever, the
folloWing plant species are presently also knoWn to contain
CPT, and extraction from such plants (methods for Which are
Within the scope of knowledge of persons reasonably skilled
in chemical extraction methodologies) Will also fall Within

rots.

the scope of the present invention:

increase, in recent times, in pathogen resistance to both

agrochemical and pharmaceutical fungicides, discovery of
neW antimicrobial compounds With neW modes of action is

becoming increasingly important. No presently-available

In vieW of the above, there exists a dire need for,

[0039] A. Camplolheca (Nyssaceae); including: Camp

not only composition(s) With effective, broad spectrum

Zolheca acuminala Decaisne, Camplolheca acuminala
var. Zenuifolia Fang et Song, Camplolheca acuminala

[0027]

anti-fungal properties, but ones Which are, to the greatest
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var. rolundifolia Yang et Duan, Camplolheca yunnan

ensis Dode, Camplolheca lowreyana Li, Camplolheca
lowreyana Li ‘Katie’, Camplolheca lowreyana Li
‘Hicksii’

B. Ervalamia (Apocynaceae);

[0055] To date, commercial CPT synthesis is not feasible,
and supplies of CPT required for the manufacture of the
drugs are noW extracted from the fruits of Camplolheca
acuminala Decaisne, Which has been listed as an endan

gered species in China since 1997.

[0040]
[0041] C. Nolhapodyles (Mappia) (Olacaceae);
[0042] D. Ophiorrhiza (Rubiaceae);
[0043] E. Merrilliodendron (Icacinaceae);
[0044] F. Mosluea (Loganiaceae);

plantations for vegetative biomass and CPT production.

[0045] G. Pyrenacanlha (Icacinaceae).

[0057] On the other hand, potential demands of trifolin

[0046] CPT, trifolin and hyperoside all exhibit unprec
edented control over plant fungal pathogens in a cost

e?fective and environmentally-safe Way, and the present
inventors believe that analogues thereof Would perform

[0056] Cultivation of the tree in the Us. is limited because
it groWs in subtropical climates. Moreover, the tree takes
approximately 10 years to produce a stable fruit yield.
Fungal diseases, particularly leaf spot and root rots, are a
main limiting factor in the cultivation of Camplolheca in

and hyperoside can be easily met because the source plants

are commonly availableieven from banana, haWthorns,
and oaks.
BRIEF DESCRIPTION OF THE DRAWINGS

likewise.

[0047] CPT, trifolin, and hyperoside de?nitely and
remarkably exhibit antifungal activity in Camplolheca
plants. In fact, CPT affects cell groWth of almost all organ
isms because it is a potent inhibitor of DNA topoisomerase.

[0048] As compared With the above-mentioned N,N-di
ethyldithiocarbamic acid sodium salt (Which shoWed only a
7-30% fungal groWth inhibition, at the same concentrations),
for example, CPT, trifolin, and hyperoside inhibited groWth
of the related fungal pathogen F avenaceum by 70% in vitro.
[0049]

The present inventors have effected a CPT-in

duced, 50% inhibition of mycelial groWth (ECSO) at rela
tively loW concentrations: approximately 10 ug/mL for E.
nigrum, R guepinii, and Drechslera sp., <25 ug/mL for A.
allernala, and <30 ug/mL for F avenaceum (Table 2).
Higher levels of CPT more effectively inhibited mycelial
groWth, but the minimal inhibitory concentration varied
betWeen the fungi: 75 ug/mL for A. allernala and E. nigrum,
100 ug/mL for Drechslera sp., 125 ug/mL forR guepinii and
F avenaceum.

[0050]

The ?avonoids Were less effective than the alkaloid

[0058]

FIG. 1 shoWs the structure of the alkaloid camp

tothecin (CPT) and the ?avonoids, namely, trifolin and
hyperoside, isolated from Camplolheca acuminala.
[0059]

FIG. 2 is a graph illustrating the effect of different

concentrations of camptothecin (CPT) and fungicides Bravo
and Maneb on mycelial groWth of Allernaria allernala.

Concentrations of CPT: 10 ug/mL (CPT-10), 25 ug/mL

(CPT-25), 50 ug/mL (CPT-50), 75 ug/mL (CPT-75), 100
ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150 ug/mL
(CPT-150); Concentration of Bravo: 10,000 ug/mL (Bravo);
Concentration of Maneb: 3,000 ug/mL (Maneb). Points and
bars represent the means and standard errors of ?ve repli
cates.

[0060]

FIG. 3 is a graph illustrating the effect of different

concentrations of camptothecin (CPT) and fungicides Bravo
and Maneb on mycelial groWth of Epicoccum nigrum.
Concentrations of CPT: 10 ug/mL (CPT-10), 25 ug/mL
(CPT-25), 50 ug/mL (CPT-50), 75 ug/mL (CPT-75), 100
ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150 ug/mL
(CPT-150); Concentration of Bravo: 10,000 ug/mL (Bravo);
Concentration of Maneb: 3,000 ug/mL (Maneb). Points and

CPT at the level of 50 ug/mL, particularly during the ?rst

bars represent the means and standard errors of ?ve repli

three Weeks of experimentation, but more effective than the
alkaloid at the level of 100 or 150 ug/mL during the Whole

cates.

experimental period.

[0061]

FIG. 4 is a graph illustrating the effect of different

concentrations of camptothecin (CPT), trifolin, and hypero

[0051] CPT, trifolin and hyperoside Were, at all experi
mental concentrations, highly effective in inhibiting Drech

side and fungicides Bravo and Maneb on mycelial groWth of
Peslalolia quepinii. Concentrations of CPT: 10 ug/mL (CPT

slera sp. and F avenaceum, and at relatively higher con

10), 30 ug/mL (CPT-30), 50 ug/mL (CPT-50), 70 ug/mL
(CPT-70), 100 ug/mL (CPT-100), 125 ug/mL (CPT-125),

centrations, CPT Was effective in suppressing groWth of A.
allernala and E. nigrum.

[0052] Over-all, the present inventors have effectively
produced, through use of CPT, trifolin, and hyperoside, a

higher e?icacy in combating fungal groWth and viability

and 150 ug/mL (CPT-150); Concentrations of Trifolin: 50

ug/mL (Trifolin-50), 100 ug/mL (Trifolin-100), and 150
ug/mL (Trifolin-150); Concentrations of Hyperoside: 50
ug/mL (Hyperoside-50), 100 ug/mL (Hyperoside-100), and

than many recently discovered and, prior to the present
invention, the most highly e?icacious antifungal agents.

150 ug/mL (Hyperoside-150); Concentration of Bravo:
10,000 ug/mL (Bravo); Concentration of Maneb: 3,000
ug/mL (Maneb). Points and bars represent the means and

[0053] The present inventors ?nd that CPTs, potent inhibi

standard errors of ?ve replicates.

tors of the enzyme DNA Topoisomerase I, has not been

previously recognized in fungicide development.
[0054]

Trifolin and hyperoside are abundant in Camplolh

eca and some other plants. Although their mechanisms of

action against fungi are unclear, their effectiveness, avail
ability, loW cost, and probable loW toxicity to humans make
the ?avonoids effective fungicides.

[0062]

FIG. 5 is a graph illustrating the effect of different

concentrations of camptothecin (CPT), trifolin, and hypero
side and fungicides Bravo and Maneb on mycelial groWth of
Drechslera sp. Concentrations of CPT: 10 ug/mL (CPT-10),

30 ug/mL (CPT-30), 50 ug/mL (CPT-50), 70 ug/mL (CPT
70), 100 ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150
ug/mL (CPT-150); Concentrations of Trifolin: 50 ug/mL

US 2007/0134282 A1

(Trifolin-50), 100 ug/mL (Trifolin-100), and 150 ug/mL
(Trifolin-150); Concentrations of Hyperoside: 50 ug/mL
(Hyperoside-50), 100 ug/mL (Hyperoside-100), and 150
ug/mL (Hyperoside-150); Concentration of Bravo: 10,000
ug/mL (Bravo); Concentration of Maneb: 3,000 ug/mL
(Maneb). Points and bars represent the means and standard
errors of ?ve replicates.

[0063]

FIG. 6 is a graph illustrating the effect of different

concentrations of CPT, trifolin, and hyperoside fungicides
Bravo and Maneb on mycelial groWth of Fusarium avenu
ceum. Concentrations of CPT: 10 ug/mL (CPT-10), 30

ug/mL (CPT-30), 50 ug/mL (CPT-50), 70 ug/mL (CPT-70),
100 ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150
ug/mL (CPT-150); Concentrations of Trifolin: 50 ug/mL
(Trifolin-50), 100 ug/mL (Trifolin-100), and 150 ug/mL
(Trifolin-150); Concentrations of Hyperoside: 50 ug/mL
(Hyperoside-50), 100 ug/mL (Hyperoside-100), and 150
ug/mL (Hyperoside-150); Concentration of Bravo: 10,000
ug/mL (Bravo); Concentration of Maneb: 3,000 ug/mL
(Maneb). Points and bars represent the means and standard
errors of ?ve replicates.
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solvent B), or reversed-phase C18 silica gel (Aldrich) using
MeOH/H2O (70:30, solvent C and 30:70, solvent D).
[0071] Leaves of C. acuminala Were collected, and air
dried young leaf material (1000 g) Was ground to a coarse

poWder and percolated With 95% EtOH ?ve times. Removal
of the solvent under a vacuum at 600 C. yielded 50 g EtOH
extract. The EtOH extract Was dissolved in MeOH/H2O

(9: 1, 500 mL) and then partitioned successively With hexane
(500 mL><5) and CHCl3 (500 mL><5) to produce a hexane
extract (20.1 g), a CHCl3 extract (18.5 g), and a MeOH/H2O
extract (12.1 g). Part of the CHCl3 extract (8.0 g) Was
fractionated on a silica gel column (300 g) using CHCl3/
EtOAc (9:1 and 4:1, each 500 mL) and then CHCl3/MeOH
(9: 1, 4:1, and 2:1, each 500 mL) to afford 50 fractions (each
50 mL), Which Were combined to six fractions of A (30 mg,
200-300 mL), B (18 mg, 800-900 mL), C (30 mg, 950-1050
mL), D (230 mg, 1150-1250 mL), E (16 mg, 1350-1450
mL), and F (6.7 g, 2100-2350 mL) on the basis oftheir TLC

pro?les. Compound 1 (200 mg) Was precipitated from
fraction D. Part of fraction F (2.0 g) Was refractionated on

a silica gel column (200 g) using CHCl3/MeOH (9:1, 4:1,
and 2:1, each 700 mL) to afford 40 fractions (each 50 mL).

[0064] FIG. 7 is a graph illustrating the CPT concentra
tions of different tissues at different ages in Camplolheca
acuminala.

[0065]

FIG. 8 is a table illustrating the experimental

concentrations of three compounds (CPT, trifolin, and
hyperoside) isolated from Camplolheca leaves for in vitro
tests against ?ve fungi isolated from Camplolheca acumi
nala.

[0066]

FIG. 9 is a table illustrating the inhibition of

alkaloid and ?avonoids isolated from Camplolheca against
mycelial groWth of fungi. Note: Both EC5O (e?fective con
centration that caused 50% inhibition of mycelial groWth)
and MIC (the minimum inhibitory concentration) are the
average of ?ve replicates measured When the fungus com
pletely covered the agar surface under control conditions.
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENT

[0067] The present invention Will be described in relation
to plant pathology, but may also have medical applications
and be extended to use in the food industry.

[0068] The present inventors have effected unprecedented
antifungal activity through use of CPT, trifolin, and hypero
side. Tests Were conducted against ?ve recently isolated

fungi (molds) from C. acuminala.
[0069] A. Extraction Procedures.
[0070]

Melting points Were measured With a MEL-TEMP

capillary melting point apparatus and Were uncorrected.
Optical rotations Were determined on a JASCO DIP-370

digital polarimeter. UV and IR Were recorded on a HeWlett
Packard 8435 spectrometer and an ATI Mattson Genesis

Series FTIR spectrometer, respectively. NMR experiments
Were performed on a Varian Unity Plus 600 MHZ spectrom
eter and NMR data are reported as 6 (ppm) value, referenced

to DMSO-d6. Silica gel (70-723 mesh, 60A, Aldrich) and
RP Silica gel (RP-18, Aldrich) Were used for loW-pressure
chromatography. TLC Was performed on silica gel 60 F254

(Aldrich) using CHCl3/MeOH (9:1, solvent A and 4:1,

Compounds 2 (301 mg) and 3 (280 mg) Were precipitated
from fractions 24-26 (1150-1300 mL) and fractions 29-30

(1400-1500 mL), respectively.
[0072] Camptothecin
(4(S)-4-ethyl-4-hydroxy-1H
pyrano-(3',4':6,7) indoliZino (1,2,-b) quinoline-3,14 (4H,
12H)-dione) (Compound 1) Was obtained as a yelloWish

amorphous solid: mp. 265-2660 C. (CHCl3); [0t]D25-56.5o
(c 0.1, DMSO); Rf 0.72 (silica gel, solvent A) and 0.63
(reversed-phase C18 silica gel, solvent C); UV (EtOH)
kmax (log 6) 218 (4.38), 262 (4.13), 330 (2.87), 370 (3.98),
380 (4.05) nm; IR vmax (KBr) 3201, 1756, 1663, 1596
cm-1; 1H NMR (DMSO-d6, 600 MHZ) 6 8.69 (1H, s, H-7),

8.16 (1H, d, J=7.8 HZ, H-12), 8.11 (1H, d, J=7.8 HZ, H-9),
7.86 (1H, t, J=7.8 HZ, H-11), 7.70 (1H, t, J=7.8 HZ, H-10),
7.37 (1H, s, H-14), 5.42 (2H, s, H-17), 5.29 (2H, s, H-5),
1.86 (2H, q, J=7.2 HZ, H-19), 0.88 (3H, t, J=7.2 HZ, H-18);
13C NMR (DMSO-d6, 150 MHZ) 6 173.6 (C, C-21), 157.6

(C, C-22), 153.5 (C, C-2), 150.1 (C, C-15), 148.1 (C, C-13),
145.9 (C, C-3), 131.5 (CH, C-7), 130.6 (C, C-6), 130.2 (CH,
C-11), 129.2 (CH, C-12), 128.7 (CH, C-9), 128.1 (C, C-8),
127.8 (CH, C-10), 120.1 (C, C-16), 96.9 (CH, C-14), 73.6
(C, C-20), 65.6 (CH2, C-17), 50.8 (CH2, C-5), 30.2 (CH2,
C-19), 7.8 (CH3, C-18).
[0073] Trifolin (kaempferol-3-O-[3-D-galactopyranoside)
(Compound 2) Was obtained as a yelloWish amorphous

solid: [0t]D25-78.6o (c 0.1, DMSO); Rf 0.51 (silica gel,
solvent B) and 0.60 (reversed-phase C18 silica gel, solvent
D); UV (EtOH) kmax (log 6) 265 (4.21), 355 (3.52) nm; IR
vmax (KBr) 3356, 3000, 1651, 1610, 1573 cm-1; 1H NMR
(DMSO-d6, 600 MHZ) 6 12.6 (1H, s, OH-5), 8.03 (2H, d,
J=9.0 HZ, H-2', H-6'), 6.87 (2H, d, J=9.0 HZ, H-3', H-540 ),
6.43 (1H, d, J=2.5 HZ, H-8), 6.20 (1H, d, J=2.5 HZ, H-6),
5.46 (1H, d, J=7.5 HZ, H-1"), 3.58 (1H, m, H-6"a), 3.56 (1H,
m, H-6"b), 3.38 (1H, m, H-5"), 3.32 (1H, m, H-2"), 3.22
(1H, m, H-3"), 3.12 (1H, m, H-4'); 13C NMR (DMSO-d6,
150 MHZ) 6 177.5 (C, C-4), 164.1 (C, C-7), 161.2 (C, C-5),
159.9 (C, C-4'), 156.4 (C, C-9), 156.2 (C, C-2), 133.2 (C,
C-3), 130.2 (CH, C-2', C-6'), 115.7 (CH, C-3', C-5'), 114.5

(C, C-1'), 104.0 (C, C-10), 101.5 (CH, C-1"), 99.1 (CH,
C-6), 94.0 (CH, C-8), 77.0 (CH, C-5"), 74.8 (CH, C-3"),
73.6 (CH, C-2"), 70.5 (CH, C-4"), 61.9 (CH2, C-6").
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[0074] Hyperoside

(quercetin-3-O-[3-D-galactopyrano

side) (Compound 3) Was obtained as a yellowish amorphous

solid: [0t]D25-81.8o (c 0.1, DMSO); Rf 0.34 (silica gel,
solvent B) and 0.75 (reversed-phase C18 silica gel, solvent
D); UV (EtOH) kmax (log 6) 256 (4.37), 356 (3.58) nm; IR
vmax (KBr) 3360, 3031, 1652, 1615, 1569 cm-1; 1H NMR
(DMSO-d6, 600 MHZ) 6 12.6 (1H, s, OH-5), 7.66 (1H, d,
J=7.8 HZ, H-6'), 7.53 (1H, br s, H-2'), 6.80 (1H, d, J=7.8 HZ,
H-5'), 6.40 (1H, d, J=2.0 HZ, H-8), 6.20 (1H, d, J=2.0 HZ,
H-6), 5.37 (1H, d, J=7.2 HZ, H-1"), 3.65 (1H, m, H-6"a),
3.57 (1H, m, H-6"b), 3.44 (1H, m, H-5"), 3.36 (1H, m,
H-2"), 3.33 (1H, m, H-3"), 3.16 (1H, m, H-4"); 13C NMR
13C NMR (DMSO-d6, 150 MHZ) 6 177.8 (C, C-4), 164.3

(C, C-7), 161.3 (C, C-5), 156.5 (C, C-9), 156.3 (C, C-2),
148.7 (C, C-4'), 144.5 (C, C-3'), 133.8 (C, C-3), 122.0 (CH,
C-6'), 121.5 (C, C-1'), 116.0 (CH, C-2'), 115.1 (CH, C-5'),
103.9 (C, C-10), 101.3 (CH, C-1"), 98.9 (CH, C-6), 94.0
(CH, C-8), 77.3 (CH, C-5"), 74.6 (CH, C-3"), 73.5 (CH,
C-2"), 70.3 (CH, C-4"), 61.5 (CH2, C-6").
[0075] B. Fungal Inhibition Experimentation.
[0076] Allernaria allernala, Epicoccum nigrum, Peslalo
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[0081] C. Findings.
[0082] 1. Antifungal Activity against Allernaria allernala.
[0083] CPT signi?cantly inhibited Allernaria groWth at
the loWest treatment concentration of 10 ug/mL (CPT-10)
(p<0.001). Colonies exposed to CPT-10 Were inhibited by
41-66%. It took 23 days for mycelium under the CPT-10
treatment to completely cover the agar surface, as compared
to 13 days under control treatment. CPT-25 (CPT at the
concentration of 25 ug/mL) Was similar to Bravo in its

ability to inhibit A. allernala (FIG. 2). Colonies in both
treatments started to groW on the second day of the experi
ment and their radii Were alWays Within about one millime
ter of one another. CPT-25 colony expansion Was reduced by
215% (28 days to cover the agar surface vs. 13 days for
control). On day 13, colonies in the CPT-25 treatment Were
52.8% smaller than controls. Thus, it is estimated that the

EC50 of CPT for A. allernala is less than 25 ug/mL. The
CPT-50 treatment Was able to inhibit fungal groWth by more
than 180%. The fungus Was totally controlled by CPT at

concentrations of 75 ug/mL (CPT-75) and above, and by the
fungicide Maneb.

Zia guepinii, Drechslera sp., and Fusarium avenaceum Were

isolated from infected leaves and roots of C. acuminala. The
strains Were cultured and maintained on potato dextrose agar

(PDA) medium.
[0077] CPT, trifolin, and hyperoside (isolated from Camp

[0084] 2. Antifungal Activity against Epicoccum nigrum.
[0085] Epicoccum nigrum greW faster than A. allernala
under control conditions in the experiment, With colonies

covering the agar surface in 10 days (FIG. 3). HoWever, this

fungi, as compard With tWo classical fungicides, Bravo

fungus Was more strongly inhibited by CPT and fungicide
than A. allernala. CPT at loW levels (10 ug/mL and 25

Zolheca as above) Were tested for their ability to inhibit these

(active ingredient: chlorothalonil) and Maneb (active ingre

ug/mL) delayed mycelial groWth of E. nigrum by 280% (28

dient: manganous ethylenebis [dithiocarbamate]), as refer
ences. The concentrations of the conventional fungicides
Were those recommended by the manufacturers (Bravo:

days to cover agar surface vs. 10 days for control). CPT-10
and CPT-25 treatments Were not signi?cantly different in

their ability to inhibit E. nigrum. On day 10, colonies in the

10,000 ug/mL; Maneb: 3,000 ug/mL).

CPT-10 treatment Were 65% smaller than controls. Thus, the

[0078] In addition to a negative control (0) and tWo
fungicides as positive controls for each of the ?ve isolated

ug/mL. Similarly to results With A. allernala, CPT-50 (CPT

pathogens, seven levels of CPT Were tested With each of the

fungi and three levels of trifolin and hyperoside Were tested
With R guepinii, Drechslera sp. and F avenaceum, respec

EC5O of CPT for E. nigrum is estimated to be less than 10

at the concentration of 50 ug/mL) inhibited groWth of E.
nigrum by more than 90% While CPT-75 (CPT at the
concentration of 75 ug/mL) and higher concentrations as

tively (see FIG. 8).

Well as Maneb totally inhibited groWth. Bravo treatment Was

[0079]

to Bravo did not start to groW until the ?fth day; by day 15
they had radii of 13 mm compared to 20 mm in CPT-25

Trifolin and hyperoside treatments Were applied at

concentrations of 50, 100, and 150 ug/mL, respectively. For
all cultures, ?nal concentrations Were made in molten (500
C.) potato dextrose agar (Difco), and 10 mL aliquots Were
poured into Petri dishes (85 mm in diameter). Within 24
hours after pouring, each of the plates Was inoculated With
one of the ?ve fungi. One 5><5 mm mycelial plug Was cut
from the actively groWing front of a 2 Week old colony, then
placed With the inoculum side doWn in the center of each
treatment plate. The cultures Were incubated at 240 C. For all

experiments, ?ve replicate plates Were inoculated for each
treatment.

[0080] Mycelial groWth on each plate Was observed daily

slightly superior to CPT-10 and CPT-25. Colonies exposed
treatment. The CPT-50 treatment Was superior to Bravo.

Under this treatment, groWth did not begin until the 8th day
of the experiment. On day 20, colony radii measured 19 mm
under Bravo treatment but only 8 mm When exposed to
CPT-50.

[0086] 3. Antifungal Activity against Peslalolia guepinii.
[0087] Peslalolia guepinii shoWed a similar groWth pat
tern to E. nigrum under control conditions (FIG. 4). CPT-10
reduced mycelial groWth by 43.5% on the 11th day When the
fungus under control treatment had covered the agar surface.

and recorded on a transparent ?lm for the ?rst tWo Weeks,

Colonies exposed to CPT-10 treatment did not reach the

then recorded on the 16th, 20th, 23rd, and 28th days. Colony
groWth rate on each plate. Mean and standard error Were

petri dish margins until day 20. Thus, it is estimated that the
EC5O of CPT for R guepinii is approximately 10 ug/mL.
HoWever, CPT totally inhibited groWth only at levels of 125
ug/mL and above. Both fungicides also successfully con

calculated from the ?ve replicates of each treatment. For

trolled P. guepinii. Trifolin and hyperoside Were similar in

each of the fungi, values of EC5O (effective concentration
that caused 50% inhibition of mycelial groWth) and MIC

their ability to inhibit R guepinii. On day 11, colonies

(the minimum inhibitory concentration) of each compound

by 53.4% and 53.8%, respectively. The EC5O of both ?a

Were estimated.

vonoids for R guepinii is estimated to be approximately 50

radii Were measured along four vertical radial directions.
The mean of the four measurements Was calculated as the

exposed to either trifolin-50 or hyperoside-50 Were inhibited
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ug/mL. However, as concentrations increased to 100 ug/mL,

ug/mL. Hyperoside at the concentration of 150 ug/mL

the ?avonoids Were more e?‘ective in inhibition of R gue

completely inhibited fungal groWth during the ?rst four

pinii than CPT; MICs of both trifolin and hyperoside for R
guepinii are most likely below 125 ug/mL, the level at Which

Weeks, While trifolin at the same level totally controlled the

CPT successfully controlled the fungus.

[0088] 4. Antifungal Activity against Drechslera sp.

fungus during the entire experiment. CPT at the concentra
tions of 125 and 150 ug/mL and Maneb also completely
inhibited groWth of F avenaceum.

[0094] Use of the agents camptothecin, trifolin and/or

[0089] Drechslera sp. greW more sloWly thanA. allernala,
E. nigrum, and R guepinii under control conditions but Was
also more sensitive to CPT, ?avonoids, and fungicides than

hyperoside in inhibiting initial fungal infestation, containing

the other fungi tested (FIG. 5). CPT at all experimental

drench applications, treatment of plant groWth medium

levels shoWed greater inhibition rates than Bravo. This

fungicide reduced mycelial groWth by 54.4% on day 20,
When control mycelium completely covered the agar sur
face. Thus, the EC5O of CPT for Drechslera is less than 10

ug/mL. HoWever, CPT only completely inhibited fungal
groWth at the concentrations of 100 ug/mL and higher.
Trifolin-50 and hyperoside-50 (trifolin and hyperoside at the
concentrations of 50 ug/mL) Were similar in their ability to

existing infestation, or reversing existing infestation can
take many forms. These may include foliar sprays, soil

(before or after plants are resident therein), and, in the case
of trees, injection into trunks or branches. The method of the
present invention is not limited to any particular form, nor
need it be in terms of novelty or obviousness, in vieW of the

completely unanticipated use of the cited compounds in the
context of anti-fungal measures, despite the compelling need
therefore.

trifolin-50 or hyperoside-50 Were inhibited by 76.1% and

[0095] Although the invention has been described With
reference to speci?c embodiments, this description is not

74.3%, respectively. Thus, the EC5O values of both ?a

meant to be construed in a limited sense. Various modi?ca

vonoids against Drechslera are less than 50 ug/mL. Hypero
side-100 (hyperoside at the concentration of 100 ug/mL)

tions of the disclosed embodiments, as Well as alternative

inhibit Drechslera. On day 20, colonies exposed to either

inhibited fungal groWth successfully With little groWth by
day 28, While trifolin-100 (trifolin at the concentration of
100 ug/mL) totally controlled the fungus over the course of
the entire experiment. CPT at the concentrations of 100
ug/mL and above, trifolin at the concentrations of 100 and

150 ug/mL, hyperoside at the concentrations of 150 ug/mL,
and Maneb completely inhibited groWth of Drechslera.

[0090] 5. Antifungal Activity against Fusarium avenu
ceum.

[0091] Fusarium avenaceum exhibited the sloWest groWth
rate of all experimental fungi under control conditions, but
Was someWhat less sensitive to CPT, ?avonoids, and fungi
cides (FIG. 6). Bravo shoWed e?‘ective inhibition of myce

embodiments of the inventions Will become apparent to
persons skilled in the art upon the reference to the descrip
tion of the invention.

[0096] It is, therefore, contemplated that the appended
claims Will cover such modi?cations that fall Within the

scope of the invention.
1 claim:

1. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:
selecting one or more plant extracts from a group con

sisting of camptothecin, trifolin and hyperoside; and
applying said one or more plant extracts to a plant.

2. The method of claim 1 further comprising the step of,

lial groWth during the ?rst several days of the experiment but

before said selecting one or more plant extracts, of extract

Was less e?fective in the later stages. On day 28, mycelium
With Bravo treatment completely covered the agar surface

ing said one or more extracts from one or more plants.

similar to the control colonies. CPT-10 Was much more

comprises plants selected from a groups consisting of:

3. The method of claim 2 Wherein said one or more plants

e?‘ective than Bravo, With 70-80% inhibition of mycelial

groWth during the ?rst several days of the experiment and
approximately 40% inhibition in the later stages. CPT-30
inhibited the rate of mycelial groWth by more than 60%.
Thus, the EC5O of CPT for F avenaceum is estimated to be

A. Plants from Camplolheca (Nyssaceae), comprising
Camplolheca acuminala Decaisne, Camplolheca
acuminala var. Zenuifolia Fang et Song, Camplolheca
acuminala var. rolundifolia Yang et Duan, Camplolh

betWeen 10 and 30 ug/mL.

eca yunnanensis Dode, Camplolheca lowreyana Li,
Camplolheca lowreyana Li ‘Katie’, Camplolheca low

[0092] Higher levels of CPT more e?cectively inhibited
mycelial groWth but complete inhibition Was not achieved
until the concentration of 125 ug/mL. Trifolin and hypero

reyana Li ‘Hicksii’;

side exhibited similar inhibition patterns at the level of 100
ug/mL, but trifolin Was more e?‘ective than hyperoside at the

concentration of 50 ug/mL. Trifolin-50 and hyperoside-50
Were less e?‘ective against E avenaceum than Bravo and

CPT-10 at the beginning of experiment but more effective
than Bravo and similar to CPT-10 during the later stages of

the experiment. On day 28, trifolin and hyperoside inhibited
fungal groWth by 35.8% and 31.6%, respectively, at the
concentration of 50 ug/mL, and by 74.8% and 72.6%,

B. Ervalamia (Apocynaceae);

C. Nolhapodyles (Mappia) (Olacaceae);
D. Ophiorrhiza (Rubiaceae);
E. Merrilliodendron (lcacinaceae);
F. Mosluea (Loganiaceae); and

G. Pyrenacanlha (lcacinaceae).
4. The method of claim 2 Wherein said one or more plants

[0093] Thus, it is estimated that EC5O values of both

is the member of the Nyssaceae family knoWn as the
Camplolheca acuminala tree.
5. A method for preventing or inhibiting the groWth of

?avonoids against E avenaceum are betWeen 50 and 100

fungal pathogens in plants comprising the steps of:

respectively, at the concentration of 100 ug/mL.
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selecting a ?rst measure of trifolin; and
applying said ?rst measure of trifolin to a plant.

6. The method of claim 5 further comprising the step of,

17. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:
selecting a ?rst measure of camptothecin; and

before said selecting said ?rst measure of trifolin, of extract
ing said trifolin from one or more plants.

7. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:
selecting a ?rst measure of hyperoside; and

applying said ?rst measure of hyperoside to a plant.
8. The method of claim 7 further comprising the step of,
before said selecting said ?rst measure of hyperoside, of
extracting said hyperoside from one or more plants.
9. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:
selecting a ?rst measure of camptothecin; and

applying said ?rst measure of camptothecin to a plant.
10. The method of claim 9 further comprising the step of,
before said selecting said ?rst measure of camptothecin, of
extracting said camptothecin from one or more plants
selected from a group consisting of:

A. Plants from Camplolheca (Nyssaceae), comprising
Camplolheca acuminala Decaisne, Camplolheca

applying said ?rst measure of camptothecin to a plant

groWth medium.
18. The method of claim 17 further comprising the step of,
before said selecting said ?rst measure of camptothecin, of
extracting said camptothecin from one or more plants.
19. The method of claim 18 Wherein said one or more

plants comprises plants selected from a groups consisting of:

A. Plants from Camplolheca (Nyssaceae), comprising
Camplolheca acuminala Decaisne, Camplolheca
acuminala var. Zenuifolia Fang et Song, Camplolheca
acuminala var. rolundifolia Yang et Duan, Camplolh

eca yunnanensis Dode, Camplolheca lowreyana Li,
Camplolheca lowreyana Li ‘Katie’, Camplolheca low
reyana Li ‘Hicksii’;

B. Ervalamia (Apocynaceae);

C. Nolhapodyles (Mappia) (Olacaceae);
D. Ophiorrhiza (Rubiaceae);

acuminala var. Zenuifolia Fang et Song, Camplolheca
acuminala var. rolundifolia Yang et Duan, Camplolh

E. Merrilliodendron (lcacinaceae);

eca yunnanensis Dode, Camplolheca lowreyana Li,
Camplolheca lowreyana Li ‘Katie’, Camplolheca low

F. Mosluea (Loganiaceae); and

reyana Li ‘Hicksii’;
B. Ervalamia (Apocynaceae);

C. Nolhapodyles (Mappia) (Olacaceae);
D. Ophiorrhiza (Rubiaceae);
E. Merrilliodendron (lcacinaceae);
F. Mosluea (Loganiaceae); and

G. Pyrenacanlha (lcacinaceae).
11. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:

G. Pyrenacanlha (lcacinaceae).
20. The method of claim 18 Wherein said one or more

plants is the member of the Nyssaceae family knoWn as the
Camplolheca acuminala tree.
21. A method for preventing or inhibiting the groWth of
molds in a substrate comprising the steps of:
selecting one or more plant extracts from a group con

sisting of camptothecin, trifolin, and hyperoside; and
applying said one or more plant extracts to said substrate.

22. The method of claim 21 further comprising the step of,
before said selecting one or more plant extracts, of extract

selecting one or more plant extracts from a group con

sisting of camptothecin trifolin and hyperoside; and
applying said one or more plant extracts to a plant groWth
medium.

12. The method of claim 11 further comprising the step of,
before said selecting one or more plant extracts, of extract
ing said one or more extracts from one or more plants.

13. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:
selecting a ?rst measure of trifolin; and

applying said ?rst measure of trifolin to a plant groWth
medium.
14. The method of claim 13 further comprising the step of,
before said selecting said ?rst measure of trifolin, of extract
ing said trifolin from one or more plants.

15. A method for preventing or inhibiting the groWth of

fungal pathogens in plants comprising the steps of:
selecting a ?rst measure of hyperoside; and

applying said ?rst measure of hyperoside to a plant

groWth medium.
16. The method of claim 15 further comprising the step of,
before said selecting said ?rst measure of hyperoside, of
extracting said hyperoside from one or more plants.

ing said one or more extracts from one or more plants.

23. The method of claim 22 Wherein said one or more

plants comprises plants selected from a groups consisting of:

A. Plants from Camplolheca (Nyssaceae), comprising
Camplolheca acuminala Decaisne, Camplolheca
acuminala var. Zenuifolia Fang et Song, Camplolheca
acuminala var. rolundifolia Yang et Duan, Camplolh

eca yunnanensis Dode, Camplolheca lowreyana Li,
Camplolheca lowreyana Li ‘Katie’, Camplolheca low
reyana Li ‘Hicksii’;

B. Ervalamia (Apocynaceae);

C. Nolhapodyles (Mappia) (Olacaceae);
D. Ophiorrhiza (Rubiaceae);
E. Merrilliodendron (lcacinaceae);
F. Mosluea (Loganiaceae); and

G. Pyrenacanlha (lcacinaceae).
24. The method of claim 22 Wherein said member of the

Nyssaceae family is the Camplolheca acuminala tree.

